{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".75","upperLimit":"38","value":"9.7"}]}],"title":"Overall Survival"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"38","value":"28.6"}]}],"title":"Responders Overall Survival"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.75","upperLimit":"38","value":"7.6"}]}],"title":"Nonresponders Overall Survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Patient's Overall Survival from date of enrollment to a minimum of three years for survival.","dispersionType":"Full Range","groups":[{"description":"ATO dosing was based on the phase 2 European Union regimen at a dose of 0.25 mg/kg administered intravenously on Days 1 through 5 during Week 1 and then twice weekly during Weeks 2 to 12, and GO at a dose of 3mg/m2 on Day 8 for 1 or 2 cycles of 12 weeks each.","id":"OG000","title":"ATO (0.25mg/kg) and GO (3mg/m2)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of enrollment to a minimum of three years for survival","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}